TY - JOUR
T1 - Incorporating coexisting chronic illness into decisions about patient selection for lung cancer screening an official American thoracic society research statement
AU - Patricia Rivera, M.
AU - Tanner, Nichole T.
AU - Silvestri, Gerard A.
AU - Detterbeck, Frank C.
AU - Tammemägi, Martin C.
AU - Young, Robert P.
AU - Slatore, Christopher G.
AU - Caverly, Tanner J.
AU - Boyd, Cynthia M.
AU - Braithwaite, Dejana
AU - Fathi, Joelle T.
AU - Gould, Michael K.
AU - Iaccarino, Jonathan M.
AU - Malkoski, Stephen P.
AU - Mazzone, Peter J.
AU - Tanoue, Lynn T.
AU - Schoenborn, Nancy L.
AU - Zulueta, Javier J.
AU - Wiener, Renda Soylemez
N1 - Funding Information:
Supported by resources from the VA Portland Health Care System, Portland, Oregon (C.G.S.). The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government.
Funding Information:
Supported by resources from the VA Portland Health Care System, Portland, Oregon (C.G.S.). The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. The chairs thank the members of the ATS Assembly on Thoracic Oncology for their support in creating this research policy statement and ATS staff members John Harmon and Kimberly Lawrence for their help in organizing the in-person meeting and conference calls. The authors thank the members of the Documents Development and Implementation Committee for their help in reviewing drafts of this report.
Publisher Copyright:
Copyright © 2018 by the American Thoracic Society.
PY - 2018/7/15
Y1 - 2018/7/15
N2 - Background: Lung cancer screening (LCS) has the potential to reduce the risk of lung cancer death in healthy individuals, but the impact of coexisting chronic illnesses on LCS outcomes has not been well defined. Consideration of the complex relationship between baseline risk of lung cancer, treatment-related harms, and risk of death from competing causes is crucial in determining the balance of benefits and harms of LCS. Objectives: To summarize evidence, identify knowledge and research gaps, prioritize topics, and propose methods for future research on how best to incorporate comorbidities in making decisions regarding LCS. Methods: A multidisciplinary group of international clinicians and researchers reviewed available data on the effects of comorbidities on LCS outcomes, focusing on the juxtaposition of lung cancer risk and competing risks of death, consideration of benefits and risks in patients with chronic obstructive pulmonary disease, communication of risk, and treatment of screen-detected lung cancer. Results: This statement identifies gaps in knowledge regarding how comorbidities and competing causes of death impact outcomes in LCS, and we have developed questions to help guide future research efforts to better inform patient selection, education, and implementation of LCS. Conclusions: There is an urgent need for further research that can help guide clinical decision-making with patients who may not benefit from LCS owing to coexisting chronic illness. This statement establishes a research framework to address essential questions regarding how to incorporate and communicate risks of comorbidities into patient selection and decisions regarding LCS.
AB - Background: Lung cancer screening (LCS) has the potential to reduce the risk of lung cancer death in healthy individuals, but the impact of coexisting chronic illnesses on LCS outcomes has not been well defined. Consideration of the complex relationship between baseline risk of lung cancer, treatment-related harms, and risk of death from competing causes is crucial in determining the balance of benefits and harms of LCS. Objectives: To summarize evidence, identify knowledge and research gaps, prioritize topics, and propose methods for future research on how best to incorporate comorbidities in making decisions regarding LCS. Methods: A multidisciplinary group of international clinicians and researchers reviewed available data on the effects of comorbidities on LCS outcomes, focusing on the juxtaposition of lung cancer risk and competing risks of death, consideration of benefits and risks in patients with chronic obstructive pulmonary disease, communication of risk, and treatment of screen-detected lung cancer. Results: This statement identifies gaps in knowledge regarding how comorbidities and competing causes of death impact outcomes in LCS, and we have developed questions to help guide future research efforts to better inform patient selection, education, and implementation of LCS. Conclusions: There is an urgent need for further research that can help guide clinical decision-making with patients who may not benefit from LCS owing to coexisting chronic illness. This statement establishes a research framework to address essential questions regarding how to incorporate and communicate risks of comorbidities into patient selection and decisions regarding LCS.
KW - Communication of risk
KW - Comorbidities
KW - Lung cancer screening
UR - http://www.scopus.com/inward/record.url?scp=85050159247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050159247&partnerID=8YFLogxK
U2 - 10.1164/rccm.201805-0986ST
DO - 10.1164/rccm.201805-0986ST
M3 - Article
C2 - 30004250
AN - SCOPUS:85050159247
VL - 198
SP - e3-e13
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
SN - 1073-449X
IS - 2
ER -